J B Chemicals & Pharmaceuticals Ltd's Q4FY25 Quarter Results
- 15 May 2025
Result Summary
- J B Chemicals & Pharmaceuticals Ltd reported a 9.6% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a growth of 14.5%.
- Its expenses for the quarter were down by 5.3% QoQ and up 10.8% YoY.
- The net profit decreased 22.4% QoQ and increased 44.0% YoY.
- The earnings per share (EPS) of J B Chemicals & Pharmaceuticals Ltd stood at 8.1 during Q4FY25.
Financial Statments for Q4FY25
| (₹ crores) | Q4FY25 | Q3FY25 | Q4FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 878.36 | 971.49 | 766.90 | -9.6% | 14.5% |
Total Expenses | 713.76 | 753.50 | 644.44 | -5.3% | 10.8% |
Profit Before Tax | 164.60 | 217.99 | 122.46 | -24.5% | 34.4% |
Tax | 38.44 | 55.50 | 34.83 | -30.7% | 10.4% |
Profit After Tax | 126.16 | 162.49 | 87.63 | -22.4% | 44.0% |
Earnings Per Share | 8.10 | 10.20 | 11.20 | -20.6% | -27.7% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
J B Chemicals & Pharmaceuticals Ltd is a leading pharmaceutical company based in India, known for its diverse range of pharmaceutical products. The company operates in the healthcare industry, focusing on the development, manufacture, and marketing of a wide array of medicines, including formulations in various therapeutic segments. As a significant player in the pharmaceutical sector, J B Chemicals & Pharmaceuticals Ltd has a strong presence both domestically and internationally. The company is committed to enhancing healthcare through its innovative products and solutions. Recent developments in the company or industry are not available in the provided data, and any major recent events are not specified here.
Revenue
During the fourth quarter of the fiscal year 2025 (Q4FY25), J B Chemicals & Pharmaceuticals Ltd reported a total income of ₹878.36 crores. This marks a decrease of 9.6% compared to the previous quarter (Q3FY25), where the total income was ₹971.49 crores. However, on a year-over-year (YoY) basis, there was a 14.5% increase from the same quarter in the previous fiscal year (Q4FY24), where total income was ₹766.90 crores. The data shows a growth in revenue when compared to the previous year, despite a decline in the quarterly performance.
Profitability
The company's profit before tax for Q4FY25 was ₹164.60 crores, reflecting a decrease of 24.5% from Q3FY25, which stood at ₹217.99 crores. Comparing it to Q4FY24, the profit before tax increased by 34.4% from ₹122.46 crores. The tax expenses for Q4FY25 were ₹38.44 crores, which is a decrease of 30.7% from Q3FY25, where taxes were ₹55.50 crores, and a 10.4% increase from Q4FY24's tax expenses of ₹34.83 crores. The profit after tax for the quarter was ₹126.16 crores, down by 22.4% from the previous quarter but up by 44.0% from the corresponding quarter of the last fiscal year. The company's earnings per share for Q4FY25 was ₹8.10, a decrease of 20.6% from Q3FY25 and a decrease of 27.7% from Q4FY24.
Operating Metrics
The total expenses for J B Chemicals & Pharmaceuticals Ltd in Q4FY25 were ₹713.76 crores, which is a reduction of 5.3% compared to the previous quarter's expenses of ₹753.50 crores. Compared to the same quarter in the previous fiscal year, expenses increased by 10.8% from ₹644.44 crores. These figures reflect the company's cost management efforts and changes in operational expenditure between quarters and years. The decline in expenses from the previous quarter and the increase from the previous year's same quarter are significant indicators of the company's operational dynamics during this period. The data provided does not include additional operational metrics such as production volumes or sales figures that could further elucidate the company's operational efficiency.